title: Glutamate receptors as therapeutic targets for Parkinson's disease.
abstract: Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms including tremor and bradykinesia. The primary pathophysiology underlying PD is the degeneration of dopaminergic neurons of the substantia nigra pars compacta. Loss of these neurons causes pathological changes in neurotransmission in the basal ganglia motor circuit. The ability of ionotropic and metabotropic glutamate receptors to modulate neurotransmission throughout the basal ganglia suggests that these receptors may be targets for reversing the effects of altered neurotransmission in PD. Studies in animal models suggest that modulating the activity of these receptors may alleviate the primary motor symptoms of PD as well as side effects induced by dopamine replacement therapy. Moreover, glutamate receptor ligands may slow disease progression by delaying progressive dopamine neuron degeneration. Antagonists of NMDA receptors have shown promise in reversing motor symptoms, levodopa-induced dyskinesias, and neurodegeneration in preclinical PD models. The effects of drugs targeting AMPA receptors are more complex; while antagonists of these receptors exhibit utility in the treatment of levodopa-induced dyskinesias, AMPA receptor potentiators show promise for neuroprotection. Pharmacological modulation of metabotropic glutamate receptors (mGluRs) may hold even more promise for PD treatment due to the ability of mGluRs to fine-tune neurotransmission. Antagonists of mGluR5, as well as activators of group II mGluRs and mGluR4, have shown promise in several animal models of PD. These drugs reverse motor deficits in addition to providing protection against neurodegeneration. Glutamate receptors therefore represent exciting targets for the development of novel pharmacological therapies for PD.
authors.affiliation: Department of Pharmacology, Vanderbilt University, Nashville, TN, USA.
authors.forename: Kari A
authors.initials: KA
authors.lastname: Johnson
authors.forename: P Jeffrey
authors.initials: PJ
authors.lastname: Conn
authors.forename: Colleen M
authors.initials: CM
authors.lastname: Niswender
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008954:Models, Biological; D009434:Neural Pathways / Q000187:drug effects / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D017470:Receptors, Glutamate / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000978:Antiparkinson Agents; D018691:Excitatory Amino Acid Antagonists; D017470:Receptors, Glutamate
references.citation: Ann Neurol. 1998 Sep;44(3 Suppl 1):S175-88
references.pmid: 9749591
references.citation: Neurology. 2000 Apr 25;54(8):1583-8
references.pmid: 10762497
references.citation: Drugs Aging. 2003;20(5):377-97
references.pmid: 12696997
references.citation: Neuroscience. 2003;122(3):747-56
references.pmid: 14622918
references.citation: J Neurochem. 1993 Oct;61(4):1191-206
references.pmid: 8376979
references.citation: J Neurosci. 2004 Jan 28;24(4):828-35
references.pmid: 14749427
references.citation: Eur J Neurosci. 2005 Oct;22(7):1799-806
references.pmid: 16197521
references.citation: J Neurosci. 1997 Jun 1;17(11):4415-25
references.pmid: 9151758
references.citation: Neurotox Res. 2007 Apr;11(3-4):151-67
references.pmid: 17449457
references.citation: Ann Neurol. 2001 Apr;49(4):525-9
references.pmid: 11310632
references.citation: Eur Arch Psychiatry Clin Neurosci. 2008 Nov;258 Suppl 5:55-9
references.pmid: 18985296
references.citation: J Neurophysiol. 1994 Aug;72(2):507-20
references.pmid: 7983515
references.citation: Neuroscience. 1998 Dec;87(4):881-91
references.pmid: 9759976
references.citation: Neuron. 2006 Oct 5;52(1):197-204
references.pmid: 17015236
references.citation: Eur J Pharmacol. 1993 Jun 11;237(1):1-7
references.pmid: 8359205
references.citation: J Neurochem. 2001 Jan;76(2):351-60
references.pmid: 11208898
references.citation: Exp Neurol. 2004 May;187(1):86-93
references.pmid: 15081591
references.citation: J Neural Transm Gen Sect. 1994;95(2):123-36
references.pmid: 7865167
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1998 Oct;358(4):500-2
references.pmid: 9826074
references.citation: Adv Exp Med Biol. 2002;513:197-223
references.pmid: 12575822
references.citation: J Med Chem. 2000 May 4;43(9):1892-7
references.pmid: 10794706
references.citation: J Neurosci. 2003 Sep 10;23(23):8302-9
references.pmid: 12967992
references.citation: Br J Pharmacol. 1997 Mar;120(6):1007-14
references.pmid: 9134210
references.citation: J Neural Transm Gen Sect. 1994;97(3):175-85
references.pmid: 7873128
references.citation: J Pharmacol Exp Ther. 2003 Aug;306(2):752-62
references.pmid: 12730350
references.citation: Pharmacotherapy. 2007 Dec;27(12 Pt 2):161S-173S
references.pmid: 18041936
references.citation: Eur J Neurosci. 2000 Jan;12(1):337-44
references.pmid: 10651888
references.citation: Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:2749-2755
references.pmid: 16278972
references.citation: Neurosci Lett. 1992 Aug 17;142(2):179-82
references.pmid: 1280793
references.citation: J Neurosci. 2007 Jun 20;27(25):6701-11
references.pmid: 17581957
references.citation: Curr Med Chem. 2008;15(7):671-84
references.pmid: 18336281
references.citation: Neurosci Lett. 1997 Dec 12;239(1):49-53
references.pmid: 9547169
references.citation: Parkinsonism Relat Disord. 2001 Jul;7(3):193-198
references.pmid: 11331186
references.citation: Ann Neurol. 1991 Nov;30(5):717-23
references.pmid: 1662477
references.citation: Neuropharmacology. 2008 Sep;55(4):483-90
references.pmid: 18625257
references.citation: Eur J Pharmacol. 1996 Apr 22;301(1-3):67-73
references.pmid: 8773448
references.citation: Annu Rev Pharmacol Toxicol. 1997;37:205-37
references.pmid: 9131252
references.citation: Neurosci Biobehav Rev. 1997 Jul;21(4):381-92
references.pmid: 9195596
references.citation: Mol Cells. 1997 Dec 31;7(6):749-54
references.pmid: 9509416
references.citation: Neuroscientist. 2005 Feb;11(1):37-49
references.pmid: 15632277
references.citation: Pharmacol Biochem Behav. 2002 Sep;73(2):455-66
references.pmid: 12117601
references.citation: Clin Neurophysiol. 2002 Nov;113(11):1667-72
references.pmid: 12417218
references.citation: Cell Tissue Res. 2004 Oct;318(1):215-24
references.pmid: 15503155
references.citation: Lancet Neurol. 2004 Dec;3(12):719-28
references.pmid: 15556804
references.citation: Ann Neurol. 1990 Oct;28(4):539-46
references.pmid: 2252365
references.citation: Neurobiol Aging. 1993 Jul-Aug;14(4):295-301
references.pmid: 8103573
references.citation: Eur J Pharmacol. 1997 Aug 6;332(2):153-60
references.pmid: 9286616
references.citation: Pharmacol Rev. 1999 Mar;51(1):7-61
references.pmid: 10049997
references.citation: J Neurochem. 1992 Aug;59(2):733-9
references.pmid: 1629743
references.citation: Br J Pharmacol. 1998 Feb;123(4):667-74
references.pmid: 9517386
references.citation: Exp Neurol. 2000 Sep;165(1):136-42
references.pmid: 10964492
references.citation: Eur J Neurosci. 2006 Jan;23(1):151-60
references.pmid: 16420425
references.citation: Exp Neurol. 2002 Jun;175(2):303-17
references.pmid: 12061862
references.citation: Eur J Pharmacol. 1995 Jan 16;272(2-3):123-9
references.pmid: 7713155
references.citation: Neurobiol Aging. 2008 Jul;29(7):1040-51
references.pmid: 17353071
references.citation: Eur J Pharmacol. 2008 Feb 2;580(1-2):95-9
references.pmid: 18035348
references.citation: Neuropharmacology. 1999 Jan;38(1):109-19
references.pmid: 10193902
references.citation: Neurobiol Dis. 2003 Dec;14(3):404-16
references.pmid: 14678757
references.citation: J Pharmacol Exp Ther. 2009 Jul;330(1):227-35
references.pmid: 19357321
references.citation: Mov Disord. 2007 Sep;22 Suppl 17:S335-42
references.pmid: 18175394
references.citation: Neuroscience. 1998 Sep;86(2):353-87
references.pmid: 9881853
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):767-73
references.pmid: 9205962
references.citation: Proc Natl Acad Sci U S A. 1985 Apr;82(7):2173-7
references.pmid: 3872460
references.citation: Neurol Sci. 2001 Feb;22(1):49-50
references.pmid: 11487196
references.citation: J Neural Transm Suppl. 1992;38:55-64
references.pmid: 1491248
references.citation: J Neurosci. 2006 Jul 5;26(27):7222-9
references.pmid: 16822979
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1993 Dec;348(6):586-92
references.pmid: 7907775
references.citation: Life Sci. 1990;47(18):PL91-7
references.pmid: 2250573
references.citation: J Neural Transm Suppl. 2006;(70):17-20
references.pmid: 17017503
references.citation: Exp Neurol. 2001 Oct;171(2):405-17
references.pmid: 11573992
references.citation: J Neurosci. 2003 Aug 6;23(18):7218-26
references.pmid: 12904482
references.citation: J Neurochem. 2001 Aug;78(3):435-45
references.pmid: 11483646
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1994 Jan;349(1):61-5
references.pmid: 7908126
references.citation: Eur J Pharmacol. 2000 Oct 20;406(3):403-10
references.pmid: 11040347
references.citation: Exp Neurol. 2005 Dec;196(2):422-9
references.pmid: 16203001
references.citation: CNS Drug Rev. 2005 Spring;11(1):77-96
references.pmid: 15867954
references.citation: J Neurosci. 2000 May 1;20(9):3085-94
references.pmid: 10777772
references.citation: Eur J Pharmacol. 2004 Feb 20;486(2):163-74
references.pmid: 14975705
references.citation: J Neurosci. 2000 Sep 1;20(17):6413-20
references.pmid: 10964947
references.citation: Exp Neurol. 1999 Jan;155(1):42-8
references.pmid: 9918703
references.citation: J Neurophysiol. 2001 May;85(5):1960-8
references.pmid: 11353013
references.citation: Neurosci Biobehav Rev. 1997 Jul;21(4):469-75
references.pmid: 9195604
references.citation: Eur J Pharmacol. 1993 Mar 2;232(2-3):247-53
references.pmid: 8385618
references.citation: J Neurosci. 2005 Nov 9;25(45):10414-9
references.pmid: 16280580
references.citation: J Neurosci. 2000 Nov 1;20(21):7871-9
references.pmid: 11050106
references.citation: Neuroreport. 2008 Jan 8;19(1):111-5
references.pmid: 18281903
references.citation: Brain Res. 2001 Apr 27;899(1-2):142-7
references.pmid: 11311875
references.citation: J Neurochem. 2003 Feb;84(4):792-802
references.pmid: 12562523
references.citation: Eur J Pharmacol. 1995 Jul 4;280(2):159-66
references.pmid: 7589181
references.citation: Neuroscience. 2003;122(3):727-37
references.pmid: 14622916
references.citation: Psychopharmacology (Berl). 2004 Sep;175(2):179-88
references.pmid: 15007533
references.citation: Neurobiol Dis. 2008 Jan;29(1):161-8
references.pmid: 17933546
references.citation: Mov Disord. 2002;17 Suppl 3:S15-21
references.pmid: 11948751
references.citation: Neurosci Biobehav Rev. 1997 Jul;21(4):455-68
references.pmid: 9195603
references.citation: Eur J Pharmacol. 1996 Oct 31;314(3):307-11
references.pmid: 8957251
references.citation: Neurology. 2001 Feb 27;56(4):455-62
references.pmid: 11222787
references.citation: J Neurosci. 2007 Aug 1;27(31):8297-308
references.pmid: 17670976
references.citation: Mov Disord. 2003 Jul;18(7):729-37
references.pmid: 12815651
references.citation: J Neural Transm Park Dis Dement Sect. 1994;8(1-2):39-71
references.pmid: 7534462
references.citation: Brain. 2002 Dec;125(Pt 12):2635-45
references.pmid: 12429591
references.citation: J Neural Transm Park Dis Dement Sect. 1991;3(3):203-13
references.pmid: 1835581
references.citation: Pharmacol Biochem Behav. 1989 Mar;32(3):621-3
references.pmid: 2544900
references.citation: J Neurophysiol. 1995 Mar;73(3):1076-83
references.pmid: 7608756
references.citation: N Engl J Med. 1998 Oct 8;339(15):1044-53
references.pmid: 9761807
references.citation: J Neurosci Res. 2005 Dec 15;82(6):778-87
references.pmid: 16273546
references.citation: Neurology. 1998 May;50(5):1323-6
references.pmid: 9595981
references.citation: J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76
references.pmid: 18344392
references.citation: J Pharmacol Exp Ther. 1999 Jun;289(3):1678-87
references.pmid: 10336568
references.citation: Br J Pharmacol. 2004 Jan;141(1):15-22
references.pmid: 14597605
references.citation: Mol Pharmacol. 2008 Nov;74(5):1345-58
references.pmid: 18664603
references.citation: Neuropharmacology. 2003 Aug;45(2):155-66
references.pmid: 12842121
references.citation: Mov Disord. 2005 Aug;20(8):919-31
references.pmid: 16007614
references.citation: Exp Neurol. 2008 Mar;210(1):109-17
references.pmid: 18035355
references.citation: Pharmacol Rev. 1966 Jun;18(2):925-64
references.pmid: 5328389
references.citation: J Neural Transm (Vienna). 1996;103(5):581-90
references.pmid: 8811503
references.citation: Ann Neurol. 1994 Jun;35(6):655-61
references.pmid: 8210221
references.citation: Suppl Clin Neurophysiol. 2004;57:733-6
references.pmid: 16106676
references.citation: J Neurosci. 2002 Jul 1;22(13):5669-78
references.pmid: 12097518
references.citation: Mov Disord. 2006 Sep;21(9):1375-9
references.pmid: 16705684
references.citation: Brain Res. 1996 Oct 14;736(1-2):202-5
references.pmid: 8930325
references.citation: Neuropharmacology. 1995 Jul;34(7):713-21
references.pmid: 8532138
references.citation: J Med Chem. 2007 Jul 26;50(15):3585-95
references.pmid: 17602546
references.citation: J Neurochem. 2007 Apr;101(2):483-97
references.pmid: 17359492
references.citation: J Neurosci. 1997 Mar 15;17(6):1891-7
references.pmid: 9045718
references.citation: Neuroepidemiology. 1993;12(4):195-208
references.pmid: 8272179
references.citation: Pol J Pharmacol. 1995 Nov-Dec;47(6):501-7
references.pmid: 8868372
references.citation: J Neurosci. 2002 Mar 15;22(6):2135-41
references.pmid: 11896153
references.citation: Mov Disord. 2005 Apr;20(4):403-9
references.pmid: 15593312
references.citation: Neuroscience. 2002;113(4):857-69
references.pmid: 12182892
references.citation: Clin Neuropharmacol. 2001 May-Jun;24(3):133-8
references.pmid: 11391123
references.citation: Ann N Y Acad Sci. 1999 Apr 30;868:531-4
references.pmid: 10414330
references.citation: Psychopharmacology (Berl). 1999 Apr;143(3):235-43
references.pmid: 10353425
references.citation: J Neural Transm. 1989;77(1):65-71
references.pmid: 2545813
references.citation: Exp Neurol. 2000 May;163(1):239-43
references.pmid: 10785463
references.citation: J Neural Transm (Vienna). 1996;103(8-9):987-1041
references.pmid: 9013391
references.citation: Psychopharmacology (Berl). 2005 Apr;179(1):154-63
references.pmid: 15672275
references.citation: J Pharmacol Exp Ther. 1993 Dec;267(3):1515-20
references.pmid: 8263813
references.citation: Eur J Neurosci. 1995 May 1;7(5):972-80
references.pmid: 7613632
references.citation: Psychopharmacology (Berl). 2005 Apr;179(1):117-27
references.pmid: 15726332
references.citation: Neuroreport. 1994 Dec 20;5(18):2586-8
references.pmid: 7696610
references.citation: Neuropharmacology. 2002 Mar;42(3):289-96
references.pmid: 11897107
references.citation: Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):297-317
references.pmid: 12769621
references.citation: Neurobiol Dis. 2006 Apr;22(1):1-9
references.pmid: 16289868
references.citation: Pharmacol Ther. 2007 Jul;115(1):116-47
references.pmid: 17582504
references.citation: J Pharmacol Exp Ther. 2005 Jun;313(3):1296-304
references.pmid: 15761115
references.citation: Neurology. 2000 Apr 25;54(8):1589-95
references.pmid: 10762498
references.citation: Clin Exp Pharmacol Physiol. 2008 Nov;35(11):1388-94
references.pmid: 18785982
references.citation: J Comp Neurol. 2000 Apr 17;419(4):407-21
references.pmid: 10742712
references.citation: Nature. 1991 Jan 31;349(6308):414-8
references.pmid: 1846943
references.citation: CNS Neurol Disord Drug Targets. 2007 Apr;6(2):87-100
references.pmid: 17430147
references.citation: Neuropharmacology. 1995 Jan;34(1):1-26
references.pmid: 7623957
references.citation: Exp Neurol. 2005 Feb;191 Suppl 1:S17-27
references.pmid: 15629758
references.citation: CNS Drugs. 2007;21(8):677-92
references.pmid: 17630819
references.citation: Arch Neurol. 1991 Sep;48(9):977-81
references.pmid: 1835370
references.citation: Pharmacol Ther. 2000 Dec;88(3):427-35
references.pmid: 11337032
references.citation: J Med Chem. 1997 Sep 12;40(19):3119-29
references.pmid: 9301676
references.citation: Eur J Neurosci. 2002 Jan;15(1):120-32
references.pmid: 11860512
references.citation: J Neural Transm Park Dis Dement Sect. 1995;10(1):27-39
references.pmid: 8619907
references.citation: J Pharmacol Exp Ther. 2007 Jan;320(1):397-409
references.pmid: 17012606
references.citation: J Neural Transm Gen Sect. 1994;98(1):57-67
references.pmid: 7710739
references.citation: Synapse. 1997 Aug;26(4):381-91
references.pmid: 9215597
references.citation: J Pharmacol Exp Ther. 1997 Jan;280(1):439-46
references.pmid: 8996226
references.citation: Neuropharmacology. 2003 Dec;45(7):895-906
references.pmid: 14573382
references.citation: Arch Neurol. 2001 Oct;58(10):1660-8
references.pmid: 11594926
references.citation: Trends Neurosci. 2000 Oct;23(10 Suppl):S28-33
references.pmid: 11052217
references.citation: Bioorg Med Chem Lett. 1999 Oct 4;9(19):2815-8
references.pmid: 10522697
references.citation: Neuropsychopharmacology. 2004 Aug;29(8):1451-61
references.pmid: 15039773
references.citation: Neuropharmacology. 2001 Sep;41(4):413-20
references.pmid: 11543761
references.citation: J Pharmacol Exp Ther. 1999 Sep;290(3):1034-40
references.pmid: 10454475
references.citation: J Neurosci. 2002 Jul 15;22(14):6176-85
references.pmid: 12122076
references.citation: J Neurol Neurosurg Psychiatry. 1992 Jul;55(7):630-1
references.pmid: 1386383
references.citation: Br J Pharmacol. 2000 Feb;129(3):541-6
references.pmid: 10711353
references.citation: J Neurochem. 1992 May;58(5):1979-982
references.pmid: 1560247
references.citation: J Comp Neurol. 1998 Jan 5;390(1):63-74
references.pmid: 9456176
references.citation: Neuroepidemiology. 1994;13(4):175-8
references.pmid: 8090259
references.citation: Brain Res Bull. 2006 Apr 14;69(3):318-26
references.pmid: 16564428
references.citation: Nat Rev Neurosci. 2005 Oct;6(10):787-98
references.pmid: 16276355
references.citation: Eur J Neurosci. 2005 Dec;22(11):2765-74
references.pmid: 16324110
references.citation: Curr Opin Neurobiol. 1996 Dec;6(6):751-8
references.pmid: 9000030
references.citation: Arch Neurol. 2007 Jan;64(1):20-4
references.pmid: 17210805
references.citation: J Neural Transm. 1989;75(3):221-6
references.pmid: 2538557
references.citation: J Neurochem. 2007 Nov;103(3):1075-91
references.pmid: 17714448
references.citation: Bioessays. 2002 Apr;24(4):308-18
references.pmid: 11948617
references.citation: J Neural Transm Park Dis Dement Sect. 1994;7(2):143-52
references.pmid: 7710666
references.citation: J Cell Physiol. 2002 May;191(2):125-37
references.pmid: 12064455
references.citation: Eur J Neurosci. 2006 Aug;24(4):1201-8
references.pmid: 16930445
references.citation: Neuropharmacology. 2005 Sep;49(4):447-55
references.pmid: 15919101
references.citation: Neuropsychopharmacology. 2009 Feb;34(3):729-38
references.pmid: 18704096
references.citation: Neuropharmacology. 2003 Jul;45(1):45-56
references.pmid: 12814658
references.citation: J Neurosci. 2006 Mar 29;26(13):3567-83
references.pmid: 16571765
references.citation: J Neurosci. 1997 Jan 1;17(1):204-15
references.pmid: 8987749
references.citation: Neuropharmacology. 2002 Aug;43(2):147-59
references.pmid: 12213269
references.citation: Mov Disord. 2002;17 Suppl 4:S13-22
references.pmid: 12211136
references.citation: J Neural Transm Gen Sect. 1992;87(1):23-35
references.pmid: 1346965
references.citation: Synapse. 2001 Oct;42(1):40-7
references.pmid: 11668589
references.citation: Neuroscience. 2007 Mar 16;145(2):611-20
references.pmid: 17224239
references.citation: FEBS J. 2008 Apr;275(7):1384-1391
references.pmid: 18279376
references.citation: Brain Res. 2005 Feb 8;1033(2):216-20
references.pmid: 15694927
references.citation: J Neurosci. 2002 Jul 1;22(13):5403-11
references.pmid: 12097492
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr;26(3):487-95
references.pmid: 11999899
references.citation: J Neurosci. 2001 Sep 15;21(18):7001-12
references.pmid: 11549710
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13668-73
references.pmid: 14593202
references.citation: Synapse. 2001 May;40(2):145-53
references.pmid: 11252026
references.citation: Curr Opin Pharmacol. 2007 Feb;7(1):39-47
references.pmid: 17088105
references.citation: J Comp Neurol. 1999 Apr 28;407(1):33-46
references.pmid: 10213186
references.citation: Acta Neurol Scand. 2007 Dec;116(6):374-9
references.pmid: 17986095
references.citation: Prog Neurobiol. 2000 Sep;62(1):63-88
references.pmid: 10821982
references.citation: Clin Neuropharmacol. 2008 Jan-Feb;31(1):51-6
references.pmid: 18303491
references.citation: Neuroreport. 2008 Mar 5;19(4):475-8
references.pmid: 18287950
references.citation: Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S3-7
references.pmid: 15885625
references.citation: Life Sci. 1990;46(1):37-42
references.pmid: 2153885
references.citation: Mov Disord. 2008 Oct 15;23(13):1860-6
references.pmid: 18759356
references.citation: J Neurosci. 1998 Dec 1;18(23):9594-600
references.pmid: 9822720